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Cystic ﬁbrosis (CF) is a major inherited disorder involving abnormalities of ﬂuid and elec-
trolyte transport in a number of different organs due to abnormal function of cystic
ﬁbrosis transmembrane conductance regulator (CFTR) protein. We recently identiﬁed a
family of CFTR activators, which contains the hit: RP107 [7-n-butyl-6-(4-hydroxyphenyl)[5H]-
pyrrolo[2,3-b]pyrazine]. Here, we further evaluated the effect of the chemical modiﬁcations
of the RP107-OH radical on CFTR activation. The replacement of the OH radical by a ﬂu-
orine atom at position 2 (RP193) or 4 (RP185) signiﬁcantly decreased the toxicity of the
compounds without altering the ability to activate CFTR, especially for RP193. The non-
toxic compound RP193 has no effect on cAMP production but stimulates the channel
activity of wild-type CFTR in stably transfected CHO cells, in human bronchial epithelial
NuLi-1 cells, and in primary culture of human bronchial epithelial cells (HBEC). Whole-
cell and single patch-clamp recordings showed that RP193 induced a linear, time- and
voltage-independent current, which was fully inhibited by two different and selective CFTR
inhibitors (CFTRinh-172 and GPinh5a). Moreover, RP193 stimulates CFTR in temperature-
rescued CuFi-1 (F508del/F508del) HBEC and in CHO cells stably expressing G551D-CFTR.
This study shows that it is feasible to reduce cytotoxicity of chemical compounds without
affecting their potency to activate CFTR and to rescue the class 2 F508del-CFTR and class
3 G551D-CFTR CF mutant activities.
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INTRODUCTION
Cystic ﬁbrosis (CF; MIM#219700) disease results from mutations
in the gene encoding the cystic ﬁbrosis transmembrane con-
ductance regulator (CFTR) protein. CFTR, which is especially
expressed at the apical membrane of the airway epithelial cells
(Kreda et al., 2005; Regnier et al., 2008), acts as cAMP-activated
chloride channel as well as a regulator of other ion channels like
the canonical Transient Receptor Potential 6, TRPC6 (Antigny
et al., 2011). In the lung, CFTR dysfunctions carry abnormal ion
transports leading to airway surface liquid volume depletion in
proximal and distal airways allowing chronic bacterial infections
and ﬁnally severe lung damages (Boucher, 1999; Tarran, 2004;
Blouquit et al., 2006).
Over 1600mutations of theCFTRgenehave been identiﬁed and
several classes of mutations according to the fate of the ﬁnal prod-
uct have been proposed (Welsh and Smith, 1993). Based on this
classiﬁcation, it is in theory possible to predict a strategy for devel-
oping a personalized CF therapy corresponding to the class of the
CFTR mutation (Becq, 2010). The majority of severe CFTR muta-
tions belongs to class 1–3 leading to reduced chloride permeability
in affected epithelia in response to cAMP agonists. Class 1 includes
non-sense, frame shift, and splice site mutations (e.g., stop muta-
tions such asG542X)with unstable transcripts and failure of CFTR
translation. Class 2 includes the most common CFTR mutation
F508del. The biogenesis of F508del mutants is extremely inefﬁ-
cient with its retention in the endoplasmic reticulum (ER) but it
is feasible to rescue the abnormal trafﬁcking by in vitro cooling
CF cells or pharmacological correctors (reviewed in Becq, 2010).
Importantly, sufﬁcient amount of rescued F508del-CFTR at the
plasma membrane conduct chloride ions despite a gating defect
(Dalemans et al., 1991; Li et al., 1993;Dormer et al., 2005). Patients
with a class 3mutation of CFTR (e.g.,G551D,G1349D) have also a
severe form of CF, because they do not have or reduced activation
of the CFTR chloride function at the plasma membrane. Class 4
mutants present defective permeation, class 5 mutants a reduced
synthesis, and class 6 is characterized by altered apical membrane
residence time of CFTR channels at the membrane (Kreindler,
2010).
Such classiﬁcation could be very helpful for mutation-oriented
search of personalized CFTR modulators. For example, the identi-
ﬁcation of pharmacological correctors of the processing defect of
CFTR could be developed only for patients diagnosed with class 2
CFTR mutations such as carrying at least one F508del mutation.
Agents directly stimulating the ion channel activity of CFTRmight
be adapted to class 3 or 4 mutations and to class 2 in combination
with a trafﬁcking corrector.
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Ourgroup is interested indevelopingnovelmodulators for class
2 and 3 CFTR defect activity. One family of CFTR modulators,
the pyrrolo[2,3-b]pyrazines, which belong to a type of derivatives
initially described as cyclin-dependent kinase (CDK)/glycogen
synthase kinase-3 (GSK-3) inhibitors, which act by competing
with ATP for binding to the kinase active site, has been identi-
ﬁed (Mettey et al., 2003; Noel et al., 2006). One compound of this
family, RP107 [7-n-butyl-6-(4-hydroxyphenyl)[5H]-pyrrolo[2,3-
b]pyrazine], has been more particularly investigated (Noel et al.,
2006) because we observed that the length of the alkyl chain is
essential for CFTR activation with the following potency: (CH2)3-
CH3 H∼=CH3 ∼= (CH2)2-CH3 ∼= (CH2)4-CH3. Based on these
observations, we decided to conserve the butyl chain in R1 posi-
tion and to modify only determinants on the phenyl ring. Four
different compounds (RP146, 173, RP185, and RP193) have been
synthesized and their effect on CFTR activity measured.
MATERIALS AND METHODS
CHEMISTRY
1H NMR spectra were recorded on a Bruker Advance DPX 300
spectrometer at 300mHz. Chemical shifts (ppm) were reported
relative to tetramethylsilane (TMS). Coupling constants (J ) were
reported in Hertz (Hz), and s, d, t, q, m, and bs referred to singlet,
doublet, triplet, quartet, multiplet, and broad singlet, respectively.
Infrared spectra (IR) were recorded on an ATI Mattson genesis
series FTIR. Elemental analyses were indicated by the symbol of
the elements, and the results were within ±0.4% (for C, H, N)
of the theoretical values unless otherwise noted; they were per-
formed on a Perkin Elmer Elemental Analyzer (2400). Melting
pointsweremeasured in open capillary tubes on anElectrothermal
9200 apparatus and are uncorrected.
All experiments involving butyllithium (BuLi) were carried out
in dried apparatus under an atmosphere of dry oxygen-free nitro-
gen. Tetrahydrofuran (THF) was distilled from benzophenone–
sodium. Diisopropylamine and heterocycles were distilled and
stored over barium oxide. Butyllithium (2.5M solution in hexane)
was supplied by Acros. Alkylpyrazines and alkylpyridines were
prepared according to usual procedures. Sodium hydride was an
95% dispersion in mineral oil. Matrex silica gel 60 Å, 20–45μm,
Merck alumina gel 90 Å, 63–200μm were employed for column
chromatographies.
GENERAL PROCEDURE FOR THE PREPARATION OF 4,7-DIAZAINDOLES
These compounds were prepared as previously described (Mettey
et al., 2003). Physical and spectral data for compound RP108 has
been reported (Mettey et al., 2003; Noel et al., 2006).
7-n-butyl-6-(4-ﬂuorophenyl)-5H-pyrrolo[2,3-b]pyrazine (RP185)
Yield 18%; white cotton; mp 161.9˚C; IR (KBr, cm-1) 3164, 3053,
2958, 2851; 1H NMR (CDCl3) δ (ppm) 11.63 (bs, 1H), 8.46 (s,
1H), 8.05 (s, 1H), 7.70–7.74 (m, 2H), 7.29 (t, J = 8.1Hz, 2H), 2.99
(t, J = 7.7Hz, 2H), 1.71–1.79 (m, 2H), 1.39–1.46 (m, 2H), 0.92 (t,
J = 7.2Hz, 3H). Anal. (C16H16N3F) C, H, N.
7-n-butyl-6-(2-ﬂuorophenyl)-5H-pyrrolo[2,3-b]pyrazine (RP193)
Yield 15%; white powder; mp 136.3˚C; IR (KBr, cm-1) 3131, 3058,
2959, 2853, 1469, 1224, 755; 1H NMR (CDCl3) δ (ppm) 10.81
(bs, 1H), 8.45 (s, 1H), 8.11 (s, 1H), 7.63 (t, J = 7.4Hz, 1H),
7.46–7.53 (m, 1H), 7.26–7.37 (m, 2H), 2.93 (t, J = 7.8Hz, 2H),
1.7–1.8 (m, 2H), 1.32–1.44 (m, 2H), 0.88 (t, J = 7.3Hz, 3H). Anal.
(C16H16N3F) C, H, N.
GENERAL PROCEDURE FOR THE PREPARATION OF COMPOUNDS, FROM
THEIR METHOXY PRECURSORS
Demethylation was performed with HBr, according to our previ-
ously described method (Mettey et al., 2003). Physical and spectral
data for compound RP107 has been reported (Mettey et al., 2003;
Noel et al., 2006).
7-n-Butyl-6-(3-hydroxyphenyl)-5H-pyrrolo[2,3-b]pyrazine
hydrobromide (RP146)
Yield 71%; mp 196.0˚C (dec); IR (KBr, cm-1) 3249, 3092, 2954,
2924, 2859, 2729; 1H NMR (DMSO-d6) δ (ppm) 12.97 (s, 1H),
8.95 (bs, 1H), 8.63 (d, J = 3Hz, 1H), 8.60 (d, J = 3Hz, 1H),
7.50 (t, J = 7.9Hz, 1H), 7.27 (d, J = 7.6Hz, 1H), 7.26 (s, 1H),
7.05 (dd, J = 7.6 and 1.6Hz, 1H), 3.01 (t, J = 7.7Hz, 2H), 1.66–
1.95 (m, 2H), 1.38–1.51 (m, 2H), 0.97 (t, J = 7.4Hz, 3H). Anal.
(C16H17N3O, HBr) C, H, N.
7-n-Butyl-6-(2-hydroxyphenyl)-5H-pyrrolo[2,3-b]pyrazine
hydrobromide (RP173)
Yield 80%; yellow powder;mp 243.0˚C (dec); IR (KBr, cm-1) 3072,
2951, 2639; 1H NMR (DMSO-d6) δ (ppm) 12.58 (bs, 1H), 9.95
(bs, 1H), 8.49 (d, J = 3Hz, 1H), 8.45 (d, J = 3Hz, 1H), 7.34–7.38
(m, 2H), 7.06 (d, J = 8.5Hz, 1H), 6.98 (t, J = 7.5Hz, 1H), 5.15 (bs,
1H), 2.76 (t, J = 7.6Hz, 2H), 1.51–1.61 (m, 2H), 1.17–1.29 (m,
2H), 0.78 (t, J = 7.3Hz, 3H). Anal. (C16H17N3O, HBr) C, H, N.
Elemental analyses
(RP173) Calcd for C16H17N3O, HBr: C, 55.18; H, 5.21; N, 12.07
Found: C, 55.02; H, 5.21; N, 12.02
(RP185) Calcd for C16H16N3F: C, 71.35; H, 5.99; N, 15.60
Found: C, 71.29; H, 5.99; N, 15.50
(RP193) Calcd for C16H16N3F: C, 71.35; H, 5.99; N, 15.60
Found: C, 71.13; H, 5.94; N, 15.58
CELL LINE CULTURE
All cell cultures were grown at 37˚C in 5% CO2 in standard
culture conditions as follows. CHO cells stably transfected with
pNUT vector alone or containing wild-type CFTR (wt-CFTR-
CHO) and the mutant G551D-CFTR (Tabcharani et al., 1991;
Becq et al., 1994, 1999) were cultured in α-minimal essen-
tial medium-GlutaMAX containing 7% of fetal bovine serum,
50 IU/ml penicillin and 50μg/ml streptomycin, and methotrex-
ate for cell selection (wt-CFTR-CHO: 100μM; G551D-CHO:
20μM; pNUT-CHO: 20μM). CuFi-1 and NuLi-1 cells derived
from human bronchial epithelium from a CF patient (CuFi-1,
F508del/F508del-CFTR mutant genotype) and a non-CF subject
(NuLi-1, wild-type CFTR). These cell lines were grown on human
placental collagen type VI (Sigma, St. Louis, MO, USA) coated
ﬂasks in BEGM medium (Cambrex Bio Science Walkersville, MD,
USA), as previously described (Zabner et al., 2003). Cells were
seeded in 24-well plates for iodide efﬂux and in 35-mm plastic
dishes for whole-cell and cell-attached patch-clamp recordings.
Culture media were renewed every 2 days.
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PRIMARY CULTURES OF HUMAN BRONCHIAL EPITHELIAL CELLS
Fragments of non-CF lungs were obtained from three patients
who underwent lung resection for cancer (three males, mean
age: 61.3± 5.5 years). Tissues were received and processed within
2 h after surgery. All procedures were performed in compliance
with the current French legislation. Human bronchi were dis-
sected free of lung parenchyma. Bronchial epithelial cells were
harvested using enzymatic isolation procedures to establish pri-
mary cultures, as previously described (Blouquit et al., 2002;
Dannhoffer et al., 2009). Brieﬂy, fragment of bronchi were incu-
bated 24 h at 4˚Cwith 0.1%protease and 0.01%deoxyribonuclease
in DMEM/Ham’s F-12 medium. Enzymatic digestion was neu-
tralized by 10% fetal bovine serum; cells were then centrifuged
at 600 rpm for 6min at room temperature (RT). Epithelial iso-
lated cells were seeded at high density on home-made permeable
collagen supports afﬁxed to an oriﬁce drilled in polycarbon-
ate cups (Blouquit et al., 2002; Dannhoffer et al., 2009). They
reached conﬂuence between 8 and 12 days after seeding. The
culture medium consisted of a 1:1 mix of Dulbecco’s modi-
ﬁed Eagle’s medium-Ham’s F-12 medium supplemented with:
5μg/ml insulin, 7.5μg/ml transferrin, 10−6 M hydrocortisone,
2μg/ml endothelial cell growth supplement, 25 ng/ml epithelial
growth factor, 3.10−8 M triiodothyronine, 2.5mM l-glutamine,
and 100 IU/ml penicillin and 100μg/ml streptomycin.
IODIDE EFFLUX
Screening of molecules and concentration response curves were
determined by measuring the rate of 125I efﬂux with a high-
capacity robotic system (MultiProbe II EXT; PerkinElmer Life Sci-
ences) adapted to the determination of iodide efﬂux as described
previously (Marivingt-Mounir et al., 2004). Time-dependent rates
(k = peak rate, min−1) of 125I efﬂux were calculated from the fol-
lowing equation: k = ln (125I t1/125I t2)/(t 1–t 2), where 125I t is the
intracellular 125I at time t and t 1 and t 2 are successive time points.
Relative rates were calculated: kpeak (peak rate of efﬂux) - kbasal
(basal rate of efﬂux; min−1), i.e., the maximal value for the time-
dependent rate (kpeak, min
−1) excluding the third point used to
establish the baseline (kbasal, min
−1). Concentration-dependent
activation curves were constructed as percentage maximal activa-
tion (set at 100%) transformed from the calculated relative rates.
In some experiments, chloride transport inhibitors were present
in the loading solution and in the efﬂux buffer. The activity of
CFTR-dependent iodide efﬂux was stimulated by 1μM forskolin
or by a cocktail containing 1μM forskolin +100μM RP deriva-
tives (146, 173, 185, or 193). The effect of RP193 100μM without
forskolin on CFTR activity was also investigated.
CYTOTOXICITY ASSAY
Todetermine effects of compounds onwt-CFTR-CHOcells viabil-
ity, colorimetric 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetra-
zolium bromide (MTT, Sigma-Aldrich) assay was performed as
previously described (Routaboul et al., 2007). Cell survival was
evaluated by measuring the mitochondrial-dependent reduction
of MTT. Cells seeded in 96-well plates were incubated during 24 h
in the presence of 100μM of the test compound (RP107, RP108,
RP146, RP173, RP185, or RP193) at 37˚C, and the MTT test was
performed the day after. At each point of treatment, cells were
washed with PBS (in mM: 130 NaCl, 2 KCl, 1.5 Na2HPO4, and 8
KH2PO4, pH 7.4). The medium was removed and 100μl of MTT
solution (0.5mg/ml in PBS) were added to each well. After 4 h of
incubation at 37˚C, the supernatant was removed and the purple
formazan crystals were dissolved by addition of 100μl dimethyl-
sulfoxide (DMSO, Sigma-Aldrich). The plates were agitated, and
the optical density was read at the wavelength of 570 nm and a
reference wavelength at 630 nm in a microplate reader (Spectra-
Count microplate photometer, Packard). Report values were the
mean of three replicates and are expressed as percentage of the
control values.
DETERMINATION OF cAMP
cAMP levels were measured using the cAMP-Screen ELISA System
(Applied Biosystems, Bedford, MA, USA). Wt-CFTR-CHO cells
were incubated with drugs for 10min at 37˚C. Reactions were ter-
minated, processed, and quantitated according to manufacturer’s
instructions.
WHOLE-CELL PATCH-CLAMP RECORDINGS
Whole-cell patch-clamp experiments were performed on wt-
CFTR-CHO and K1-CHO,which did not expressed CFTR, cells at
RT. Currents were recorded with a RK-400 patch-clamp ampliﬁer
(Biologic,Claix, France). Current–voltage (I/V) relationships were
constructed by clamping the membrane potential to −40mV and
by pulses from−100 to+100mVwith 20mV increments. Pipettes
were pulled from borosilicate glass capillary tubing (GC150-TF10;
Clark Electromedical Inc., Reading, UK) using a two-step ver-
tical puller from Narishige (Tokyo, Japan) and had a resistance
from 3 to 5MΩ. They were ﬁlled with the following solution
(in mM: 1 NaCl, 113 l-aspartic acid, 113 CsOH, 1 MgCl2, 27
CsCl, 1 EGTA, 10 TES, and 3 MgATP, ex temporane, pH 7.2; 285
mOsm). They were connected to the head of the patch-clamp
ampliﬁer through an Ag–AgCl pellet. The bath solution con-
tained in mM: 145 NaCl, 4 CsCl, 1 CaCl2, 1 MgCl2, 10 glucose,
and 10 TES (pH 7.4; 340 mOsm). The liquid potential was cor-
rected before seal establishment. Seal resistances ranging from
5 to 10GΩ were obtained. Pipette capacitances were electroni-
cally compensated in cell-attached mode. Membrane capacitances
were measured in the whole-cell mode by ﬁtting capacitance
currents obtained in response to a hyperpolarization of 10mV,
with a ﬁrst-order exponential, and by integrating the surface of
the capacitance current. Sample frequency was 3 kHz. Results
were analyzed with the pClamp9 package software (Molecular
Devices, Sunnyvale, CA, USA). Mean values of membrane capac-
itance were 39.1± 6.0 pF (n = 14) for wt-CFTR-CHO cells. For
graphic representations, I/V relationship was normalized to 1 pF
to remove variability due to differences in cell sizes. For time course
experiments, current amplitude measured at +40mV was plotted
each 10 s.
SINGLE-CHANNEL PATCH-CLAMP RECORDINGS
Single-channel currents were recorded from cell-attached patches.
Pipettes were pulled from borosilicate glass capillary tubing
(GC150-F10; Clark Electromedical Inc., Reading, UK) using a
two-step vertical puller from Narishige (Tokyo, Japan) had a resis-
tance of 15–30MΩ. Seal resistances ranging from 10 to 20GΩ
were obtained. Experiments were performed at RT. Cells were
stimulated with forskolin (1μM) and RP193 (10μM). Results
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were displayed conventionally with inward currents (outward ﬂow
of anions) indicated by downward deﬂections. In all the ﬁgures,
dashed lines give the zero current baseline when the channels are
in the closed state. Potentials were expressed as the bath potential
minus the patch electrode potential. Single-channel recordings
were sampled at 3 kHz and ﬁltered at 100Hz with an eight-pole
Bessel ﬁlter. The pipette solution contained in mM: 150 NaCl, 2
MgCl2, and 10 TES (pH= 7.4); the bath contained: 145 NaCl, 4
KCl, 2 MgCl2, and 10 TES (pH= 7.4).
Transepithelial ion transports
Conﬂuent human bronchial epithelial cell cultures were mounted
in Ussing chambers, bathed on both sides with Krebs bicarbonate
Ringer (KBR) solution warmed at 37˚C, and gassed with 95% O2-
5% CO2. KBR composition was in mM: 119.7 NaCl, 15 NaHCO3,
10 glucose, 4.5 KCl, 2 CaCl2, 1.5 NaH2PO4, 0.7 Na2HPO4, 0.23
MgCl2. The short-circuit current (I sc) was monitored continu-
ously using a VCC MC2 voltage clamp (Physiologic Instruments
Inc., San Diego, USA). One voltage-sensing electrode and one
current-passing electrode were placed on each side of the culture.
The transepithelial resistance (Rt) was determined by clamping
the potential difference (PD) to +2mV at 90 s intervals, recording
the deﬂection in short-circuit current (I sc), and applying Ohm’s
law. Cell cultures were allowed to equilibrate until stabilization
of bioelectric variables, which required approximately 20–30min.
Basal bioelectric activity was monitored for an additional 10min
period prior to the addition of drugs. The pharmacological agent
amiloride (an inhibitor of the epithelial sodium channel, ENaC)
and forskolin (an activator of adenylate cyclase) were then added
sequentially, and the bioelectric activity was allowed to stabilize
10–15min before addition of the subsequent agent. Amiloride
(10μM) was added to the apical bath, forskolin (1μM) was
added to the apical and the basolateral baths and RP193 (100 and
200μM) was added to the basolateral bath. Changes in I sc were
calculated as the difference between the values measured immedi-
ately before the addition of reagents, and the values corresponding
to the plateau phase after the addition of amiloride, forskolin, and
RP193.
CHEMICALS
All culture media, hormones, growth factors, or antibiotics
were from Invitrogen (Cergy-Pontoise, France) or Sigma (Saint
Quentin Fallavier, France), and FBS was from PerbioScience (Bre-
bières, France). Unless otherwise stated, chemicals were purchased
from Sigma.
RESULTS
EFFECT OF THE NEWLY SYNTHESIZED COMPOUNDS ON CFTR
We ﬁrst examined the effects of the modiﬁed pyrrolo[2,3-
b]pyrazine derivatives (Figure 1A) on CHO cells stably express-
ing wt-CFTR with a cell-based primary screening assay using
iodide efﬂux measurement (Marivingt-Mounir et al., 2004). All
compounds stimulated CFTR with various half-maximal effec-
tive concentrations. For the most potent compound, RP193 we
determined an EC50 of 270 nM. Then, for RP173 we obtained an
EC50 of 0.2μM. Finally for the two remaining compounds we
found much higher values with or EC50 = 78μM for RP185 and
EC50 = 97μM for RP146 (Figure 1B). Before extensive analysis
of the activation of CFTR by these compounds, their cytotoxicity
has been evaluated by measuring cellular dehydrogenase activ-
ity using the water-soluble tetrazolium salt MTT. Importantly,
we observed that the two compounds with a ﬂuorine atome on
the phenyl ring, at the position 2 (RP193) or 4 (RP185) are not
cytotoxic (Figure 1C). These experiments also revealed that the
others compounds (RP107, RP108, RP146, and RP173) have a
signiﬁcantly higher cytotoxicity compared to the control condi-
tions. Thus, among the pyrrolo[2,3-b]pyrazine derivatives tested
here and previously (Noel et al., 2006) the compound 7-n-butyl-
6-(2-ﬂuorophenyl)-5H-pyrrolo[2,3-b]pyrazine named RP193 is
the less toxic derivative and the most potent activator of wt-
CFTR. Iodide efﬂux experimentswere then performedwithRP193
without forskolin 1μM on wt-CFTR-CHO cells and revealed no
stimulation of CFTR activity (Figure 1D). Further experiments
revealed that potentiation of CFTR activity by RP193 (Figure 1D)
was independent of intracellular cAMP levels (Figure 1E).
ACTIVATION OF A LINEAR CFTR Cl− CURRENT BY RP193
We performed whole-cell patch-clamp experiments to record
CFTR chloride currents after stimulation of wt-CFTR-CHO
cells by RP193. Characteristic whole-cell currents and the cor-
responding current/voltage plots in the absence and presence
of RP193 are presented Figure 2. In the absence of any acti-
vator, no or very small current was recorded (Figures 2A,B,D,
noted basal). Addition of low concentration of forskolin (1μM)
into the bath stimulated a time- voltage-independent and lin-
ear conductance with small amplitude, suggesting the presence
of a functional CFTR (Figures 2A,B,D, noted fsk). Addition
of 10μM RP193 (Figures 2A,B,D, RP193) in the presence of
1μM fsk induced a large and signiﬁcant increase of the CFTR
current amplitude compared to basal current and to forskolin-
induced current. When measured at +40mV the amplitude val-
ues are: basal, 1.8± 0.4 pA/pF; fsk, 18.4± 6.2 pA/pF; fsk+RP193,
113.8± 15.1 pA/pF. This current was fully and rapidly inhibited
by two selective CFTR inhibitors; CFTR-inh172 (10μM, current
amplitude at+40mV:8.2± 5.2 pA/pF) andGPinh5a (100 pM,cur-
rent amplitude at +40mV: 11.6± 7.7 pA/pF; Figures 2A,B,D).
As expected, we observed no effect of either forskolin (1μM)
or RP193 (10μM) in CHO-K1 (Figure 2C). The time course
of the activation and inhibition of CFTR currents from two dif-
ferent whole-cell recordings is shown in Figure 3. Addition of
RP193, in presence of forskolin, induced a signiﬁcant increase of
the current within 5–7min, which was fully and rapidly inhibited
by the addition of either CFTR-inh172 (Figure 3A) or GPinh5a
(Figure 3B).
ACTIVATION OF CFTR CHLORIDE CHANNELS BY RP193
We performed single-channel patch-clamp experiments to record
CFTR activity in the presence of RP193. In basal condition no
spontaneous channel activity was detected in cell-attached con-
ﬁguration (Figure 4A, left part of the exemplar tracing). In the
presence in the bath of a low concentration of forskolin (1μM)
we recorded little CFTR activity (Figure 4A, middle part of
the exemplar tracing). Following addition to the bath of RP193
(10μM) progressive and sustained CFTR activity was recorded
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FIGURE 1 | (A) Chemical structure of the 2 pyrrolo[2,3-b]pyrazines previously
tested compounds (RP107 and RP108) and newly synthesized compounds
(RP146, 173, 185, and 193). (B) EC50 of different compounds tested
determinate by iodide efﬂux in wt-CFTR-CHO. (C) Evaluation of the
cytotoxicity of the six different derivatives. The toxicity of the compounds was
evaluated as described in the experimental section. Results are presented as
percentage of cell viability for wt-CFTR-CHO cells treated 24 h with 100μM of
each compound; n =20 for each compound, except for RP146, n =3 and for
DMSO 100% and DMSO 0.1%, n =10. (D) Bar chart showing RP193
(100μM), forskolin (1μM), and forskolin (1μM)+RP193 (100μM) dependent
iodide efﬂux in wt-CFTR-CHO cells. n =4 for each. (E) Bar chart showing
cAMP levels in wt-CFTR-CHO cells stimulated by RP193 (100μM), forskolin
(1μM)+RP193 (100μM), or forskolin (1μM). Data are expressed as the
mean±SEM of 8–16 measurements normalized to cAMP levels in the
presence of 10μM forskolin (100%) and are representative of two
independent experiments. Ns: no signiﬁcant differences with respect to
experimental condition in which DMSO 0.1% was added, ***p<0.001 using
the t -test.
(Figures 4A,B). After excision of the membrane in the presence of
1μMforskolin and 10μMRP193 in the bath,we observed the typ-
ical run down (Becq, 1996) of CFTR channels (Figure 4B) leading
to complete closure of CFTR channels. The average unitary con-
ductance of 8.1± 0.0 pS calculated in these experiments (n = 4) is
consistent with previous data obtained using cAMP agonists (Becq
et al., 1999; Kammouni et al., 1999; Figures 4C,D).
RP 193 ACTIVATES TWO CFTR MUTANTS G551D- AND F508del-CFTR
CAUSING SEVERE CF DISEASE
To determine whether RP193 could activate CFTR mutants, we
performed iodide efﬂux experiments with cells expressing two of
the most frequent CF mutations, the class 3 CF mutation G551D-
CFTR, studied in CHO cells stably expressing G551D-CFTR, and
the class 2 CF mutation F508del-CFTR, studied in CuFi-1 cells
derived from a human CF bronchial epithelium (F508del/F508del
genotype). As CuFi-1 cells are CF bronchial epithelial cells, we
also compared the effect of RP193 on NuLi-1 cells derived from
a non-CF human bronchial epithelium. RP193 (100μM) stim-
ulated CFTR in NuLi-1 cells in presence of forskolin (10μM;
Figures 5A,B). This effect was abolished by the selective CFTR
inhibitor CFTR-inh172 (10μM, Figure 5B). RP193 did not stimu-
late iodide efﬂux in CuFi-1 cells with the F508del-CFTR mutation
cultivated at 37˚C (Figure 5C). Then, CuFi-1 cells were incubated
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FIGURE 2 | Activation of CFTR current in CHO cells. Representative
current traces for CFTR are shown in the basal state and after successive
addition of forskolin (1μM), RP193 (10μM), and speciﬁc CFTR inhibitor
CFTR-inh172 (10μM) (A) or GPinh5a (100 pM) (B). (C) Representative current
traces recorded after the successive addition of forskolin (1μM) and RP193
(10μM) in CHO-K1. Step protocol consisted of 300ms voltage from −100
to +100mV from a holding potential of −40mV. (D) I/V curves (mean±SE)
for CFTR current in the four experimental conditions for the three different
protocols used.
FIGURE 3 | Representative time course of whole-cell activation and
inhibition of CFTR current at +40mV. (A) Sequential addition of Fsk
(1μM), RP193 (10μM), and CFTR-inh172 (10μM) and (B) sequential addition
of Fsk (1μM), RP193 (10μM), and GPinh5a (100 pM). Horizontal bars
represent time of perfusion of different drugs.
for 24 h at low temperature (27˚C) to rescue F508del-CFTR (Den-
ning et al., 1992). In these conditions of culture and in pres-
ence of forskolin 10μM, RP193 induced an iodide efﬂux signiﬁ-
cantly higher than with forskolin alone (Figures 5D,E). In further
experiments, CuFi-1 cells were incubated 24 h at 37˚C with the
pharmacological corrector miglustat in order to rescue F508del-
CFTR (Norez et al., 2006). Following this treatment of CuFi-1
cells, RP193 signiﬁcantly induced a higher iodide efﬂux than in
basal conditions or with forskolin alone (Figure 5F), conﬁrming
the functional rescue of F508del-CFTR proteins. This efﬂux was
fully inhibited in presence of the CFTRinh-172 (10μM, data not
FIGURE 4 | Single CFTR chloride channel activation by RP193 in
wt-CFTR-CHO cells. (A) Continuous cell-attached recording obtained on a
wt-CFTR-CHO showing the activation of CFTR chloride channel by 10μM of
RP193 in the bath in presence of forskolin (1μM) at the potential of
+60mV. (B) Representative recording of rundown of CFTR after channel
excision in presence of RP193 (10μM). Insert depicts 1min of channel
opening recording in cell-attached conﬁguration. (C) Representative
recordings at various patch potentials as indicated in the presence of RP193
at (10μM) in the bath and the associated I/V curve (D).
shown), and no effect of RP193 was observed in CuFi-1 cells non-
treatedwithmiglustat (Figure 5F). Thus RP193 is able to stimulate
F508del-CFTR activity after maneuvers leading to the correction
of its abnormal trafﬁcking.
We also performed iodide efﬂux experiments onG551D-CFTR-
CHO cells. No signiﬁcant stimulation was observed compared
to basal state with 10μM forskolin alone (Figure 5G). However,
RP193 10μM stimulated an efﬂux in G551D-CFTR-CHO cells in
presence of forskolin 10μM (n = 4,Figure 5G) while RP193 alone
did not have any effect (not shown). Taken together these exper-
iments revealed that RP193 is able not only to activate wt-CFTR
but also rescued F508del-CFTR and G551D-CFTR.
ACTIVATION OF CFTR CHLORIDE CHANNELS BY RP193 IN PRIMARY
CULTURES OF HUMAN BRONCHIAL EPITHELIAL CELLS
Ten primary cultures of human bronchial epithelial cells (HBEC)
were studied inUssing chambers. ThemeanPD, I sc, andRt of these
cultures were respectively: −4.7± 0.6mV, 53.4± 7.2μA/cm2,
and 98.8± 14.8Ω cm2. Addition of amiloride (10μM) to the
luminal bath signiﬁcantly reduced I sc in the preparations
(−29.5± 4.5μA/cm2). In the presence of amiloride, the addition
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FIGURE 5 | Examples of iodide efflux curves as function of time on
NuLi-1 cells (A), CuFi-1 (C) cultured at 37˚C and CuFi-1 treated by low
temperature (24h, 27˚C) (D) in basal conditions, stimulated by forskolin
(10μM), or by forskolin (10μM) and RP193 (100μM). Bar chart showing
iodide efﬂux experiments on NuLi-1 (B), CuFi-1 treated by low temperature
(24 h, 27˚C) (E), CuFi-1 treated with miglustat (24 h, 100μM) (F) and
G551D-CHO cells (G). Cells were successively treated with forskolin
(10μM) and RP193 (100μM) and NuLi-1 cells were equally treated by
CFTR-inh172 (10μM), n =4 for each. *p<0.05 and **p<0.01 using the
t -test.
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FIGURE 6 | Bar chart representing I sc variations in primary culture of
human bronchial epithelial cells in response to RP193 (100 and
200μM) in presence of amiloride 10μM and forskolin 1μM, n =10 for
each. ***p<0.001 using the t -test.
of forskolin (1μM) induced a signiﬁcant increase in I sc in HBEC
cultures (0.4± 0.1μA/cm2). Successive addition of RP193 (100
and 200μM) increased signiﬁcantly I sc from respectively 0.5± 0.2
and 1.1± 0.3μA/cm2 (Figure 6) indicating that RP193 is able to
increased I sc in primary cultures of HBEC.
DISCUSSION
Based on previously published data from our laboratory, one of
the main objective of this ligand-based study was to evaluate the
effects of the modiﬁcation of determinants on the phenyl ring
of the pyrrolo[2,3-b]pyrazines family on their potency to acti-
vate CFTR. Firstly, we translocated the 4-OH substituent of the
phenyl ring of RP107, in position 2 (compound RP173) and in
the position 3 (compound RP146). Secondly, based on results
obtained with a 4-Cl substituent (RP108; Noel et al., 2006), we
tested another halogen substituent at the same position on the
phenyl ring: 4-F (RP185) and in position 2-F (RP193). Ability
of these newly synthesized compounds to activate wt-CFTR, was
assessed by iodide efﬂux, which allowed us to identify RP193 as a
new cAMP-independent hit of the pyrrolo[2,3-b]pyrazines family
(EC50 = 270 nM).Most importantly,RP193 appeared to be signiﬁ-
cantly less toxic than compounds developed previously as revealed
by cytotoxicity assays. To complete our study of RP193 com-
pound, we performed patch-clamp experiment in the whole-cell
and the cell-attached conﬁgurations,which conﬁrmed its ability to
activate wt-CFTR. As lung pathology represents the most drastic
syndrome in CF (Boucher, 1999), another important objective of
this work was to evaluate the effect of RP193 on CFTR activity in
cultures of human bronchial non-CF and CF epithelial cells. We
then performed iodide efﬂux experiment on cells,which expressed
two of the most common mutation encountered in CF patients.
Our data demonstrated that RP193 was able to stimulate rescued
F508del-CFTR and G551D-CFTR.
A recent study carried out in our laboratory demonstrated the
ability of RP compounds previously described as CDK/GSK-3
inhibitors, to activate CFTR with a strong afﬁnity (Noel et al.,
2006). It was shown that RP107 was able to stimulate wt-CFTR
with a submicromolar afﬁnity by a cAMP-independent mecha-
nism. The importance of the length of the alkyl chainwas observed
with the best activation of CFTRobtainedwith compounds having
a butyl chain. This property was conserved in the newly synthe-
sized compounds, and only the nature and/or the position of the
substituent on the phenyl ring were changed. Firstly, transloca-
tion of the OH substituent at position 2 (RP173) or at position
3 (RP146) reduced the potency of the compound suggesting that
the position of this substituent on the phenyl ring is an important
determinant for the ability to activate CFTR.
Experiments performed with RP108 demonstrated efﬁciency
to activate wt-CFTR of compound with a halogen substituent
(Noel et al., 2006). Other studies demonstrated efﬁciency
of compounds, like the benzimidazolone NS004 or 1,2,3,4-
tetrahydroisoquinoline-3-carboxylic acid diamides, to activate
CFTR with different halogen substituent in their structure
(Gribkoff et al., 1994; Devor et al., 2000; Hirth et al., 2005; Murthy
et al., 2005) suggesting that these derivatives could play an impor-
tant role in the activation of CFTR. Substitution of the chlorine
atom by another halogen, a ﬂuorine atom, at position 4 (RP185)
or position 2 (RP193) of the phenyl ring was then performed.
It was shown that ﬂuoride, the reduced form of ﬂuorine, stimu-
lated phosphorylated CFTR most probably by direct interaction
with NBD2 domain and by slowing CFTR channel closure (Berger
et al., 1998). Caci et al. (2003) also demonstrated activation of
CFTR by a compound containing F residue. In their study, these
authors demonstrated that UCCF-853 is an activator of CFTR-
dependent Cl− secretion in intact human airway epithelium.
Iodide efﬂux experiments revealed that our compounds poten-
tiated CFTR activity with a higher potency for RP193. Marivingt-
Mounir et al. (2004) already tried to introduce a ﬂuorine atom
in another class of CFTR activators, the benzo[c]quinoliziniums.
However,no activationof CFTRwas foundwith these compounds.
Nevertheless, contrary to MPB104, the most active compound in
their study, MPB with a ﬂuorine substituent did not have a butyl
chain,which appeared to be a key determinant forCFTRactivation
by RP agents.
Interestingly, RP107 and RP193 presented similar EC50 values
for CFTR potentiation in iodide efﬂux (EC50 are respectively 150
and 270 nM). Nevertheless, cytotoxicity assays revealed that com-
poundswith chlorine atomor hydroxyl radical aremore toxic than
compounds with ﬂuorine atom whatever the position of the sub-
stituent is (2 or 4 on the phenyl ring). To our knowledge, there
are no comparative studies of cell toxicity of compounds with
or without a ﬂuorine atom. The addition of the ﬂuorine atom
could then reduce cell toxicity of compounds that are still able to
activate phosphorylated CFTR. These observations could provide
some clue to generate new potent CFTR activators (importance
of the OH radical) with less cytotoxicity (addition of a ﬂuorine
atom).
We demonstrated that RP193 is able to potentiate wt-CFTR
in CHO cell line. It appeared then important to test this com-
pound on CFTR mutant. First, we performed experiments on
human bronchial epithelial cell expressing endogenousWT-CFTR
or F508del-CFTR, the most common mutation in CF patients.
RP193 potentiated WT-CFTR activity, as observed in other cell
type, but it was also able to potentiate F508del-CFTR corrected
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either by low temperature incubation or by a 24-h-miglustat-
treatment. Secondly,we performed experiments onG551D-CFTR,
a class 3 mutation retrieved in patients with severe disease and
which present no or reduced activation of the CFTR chloride
function. Our studies revealed that in presence of a low forskolin
concentration, RP193 potentiates the activity of G551D-CFTR. It
should be noted that forskolin alone did not have any effect as pre-
viously demonstrated (Becq et al., 1994; Illek et al., 1999). Thus, the
ability of RP193 compound to activate two of the most common
CFTR mutants is very interesting in the perspective of develop-
ing CF pharmacotherapy. A recent study demonstrated that the
use of pharmacological activator of CFTR could, in particular,
improve lung function inpatientswithG551D-CFTRshowing that
pharmacological treatment in CF is a realistic objective (Accurso
et al., 2010). Our approach developed here is clearly in this
line.
In conclusion,our study emphasizes the importanceof thepres-
ence of an OH radical in compounds in order to activate CFTR.
We equally revealed that presence of a ﬂuorine atom could reduce
cytotoxicity without altering efﬁciency of the compound to stim-
ulate phosphorylated CFTR. Finally, we identiﬁed RP193 as a new
compound able to stimulate, through a cAMP-independent path-
way, wt-CFTR, rescued F508del-CFTR, and G551D-CFTR activity
in HBEC.
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